BioCentury

7:00 AM GMT, Aug 20, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/17 cls
Array BioPharma Inc. (NASDAQ:ARRY) Leerink Howard Liang Upgrade Outperform (from market perform) 21% $5.50
Liang also raised his target to $8 from $4 on "promising" Phase II data for MEK inhibitors selumetinib and MEK126 (formerly ARRY-162). In May, Array reported Phase II data in patients with mutant K-Ras(KRAS)

Read the full 754 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.